Clinical trialNCT07061574RecruitingPhase 1/PHASE2Interventional

A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes

SponsorCity of Hope Medical CenterEnrollment120New OnsetType 1 Diabetes

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This multi-center randomized controlled trial will assess the safety and efficacy of ATG followed by either adalimumab or verapamil in preserving insulin secretion 2 years from randomization in persons aged 9 to \<21 with recent-onset stage 3 T1D.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Alberto Pugliese, MD
City of Hope Medical Center
Study Chair
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

11 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Ucsf
San Francisco, California, United States
Stephen Gitelman, MD
Recruiting
Barbara Davis Center for Diabetes University of Colorado Anschutz
Aurora, Colorado, United States
Andrea Steck, MD
Not, yet, recruiting
Yale University
New Haven, Connecticut, United States
Laura Nally, MD
Recruiting
University of Florida
Gainesville, Florida, United States
Laura Jacobsen, MD
Recruiting
University of Miami
Miami, Florida, United States
David Baidal
Recruiting
Indiana University
Indianapolis, Indiana, United States
Linda DiMeglio, MD, MPH
Recruiting
University of Minnesota
Minneapolis, Minnesota, United States
Antoinette Moran, MD
Recruiting
University of Buffalo
Buffalo, New York, United States
Teresa Quattrin, MD
Recruiting
University of Pittsburgh
Pittsburgh, Pennsylvania, United States
Ingrid Libman, MD
Recruiting
Baylor College of Medicine
Houston, Texas, United States
Rebecca Aguirre, MD, PhD
Recruiting
Seattle Children'S Hospital
Seattle, Washington, United States
Petter Bjornstad, MD
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Adalimumab →Lymphocyte immune globulin, anti-thymocyte globulin →Verapamil extended-release capsule

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 10 Mar 2026
Primary completion: 15 Apr 2030
Completion: 15 Apr 2031
Last update posted: 21 Aug 2026
Registered enrollment: 120
Registry id: NCT07061574

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.